Table 4.
Patients with VTE vs. no VTE
| VTE (N =11) | No VTE (N = 359) | p value | |
|---|---|---|---|
| Age in years at first hospitalization (median, IQR) | 6.8 (2.6, 10.7) | 6.2 (3.4, 10.7) | 0.869 |
| Sex (n, %) | 0.348 | ||
| Male | 5 (45.5) | 222 (61.8) | |
| Race/ethnicity (n, %) | 0.369 | ||
| White | 6(75) | 139 (45.9) | |
| Hispanic | 0 (0) | 62 (20.5) | |
| Black | 1 (12.5) | 69 (22.8) | |
| Other | 1 (12.5) | 33 (10.9) | |
| Clinical pattern ofNS (n, %) | 0.842 | ||
| Steroid sensitive-infrequently relapsing | 3 (27.3) | 101 (28.1) | |
| Steroid sensitive-frequently relapsing | 2 (18.2) | 56(15.6) | |
| Steroid sensitive-steroid dependent | 2 (18.2) | 86 (24.0) | |
| Steroid-resistant | 3 (27.3) | 96 (26.7) | |
| Congenital or infantile | 0(0) | 5 (1.4) | |
| Biopsy diagnosis (n, %) | 0.438 | ||
| Minimal change disease (± mild mesangial hypercellularity) | 6 (54.6) | 105 (29.3) | |
| FSGS or FGGS | 2 (18.2) | 83 (23.1) | |
| Membranous, MPGN, others | 0 (0) | 24 (6.7) | |
| No biopsy | 3 (27.3) | 137 (41.0) | |
| Baseline eGFR ml/min/1.73m2 (median, IQR) | 119.2(77.4, 131.5) | 129.1 (97.1, 171.9) | 0.086 |
| Number of hospitalizations | 2 (1,3) | 1 (1,2) | 0.412 |
| (median, IQR) | |||
| Overall hospital days | 22 (16, 26) | 6 (3, 11) | <0.001 |
| ICU days | 4 (0, 15) | 0 (0, 0) | <0.001 |
| Number of infections | 1 (0, 2) | 0 (0, 1) | 0.046 |
VTE venous thromboembolism, NS nephrotic syndrome, eGFR estimated glomerular filtration rate, ICU intensive care unit, FGGS focal global glomerulosclerosis, FSGS focal segmental glomerulosclerosis, MPGN membranoproliferative glomerulonephritis